Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015).

Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015). by Sader HS, Huband MD, Duncan LR and Flamm RK published in Pediatr. Infect. Dis. 2018; J. 37 (6): 549-554

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). by Pfaller MA, Sader HS, Castanheira M, Flamm RK and Mendes RE published in J. Antimicrob. Chemother. 2018; 73 (4): 916-922

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. by Pfaller MA, Sader HS, Flamm RK, Castanheira M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2018; 91 (2): 199-204

Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Int. J. Antimicrob. Agents. 2018; 52 (2) 287-292

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China. by Sader HS, Dale GE, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (7): e00311

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. by Pfaller MA, Rhomberg PR and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 43-45

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing.

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing. by Bradford PA, Huband MD and Stone GG published in Antimicrob. Agents Chemother.: in press, 2018.

Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016.

Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016. by Sader HS, Castanheira M, Duncan LR and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 69-74

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design.

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design. Lead author: MD Huband, presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2492

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2432

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program.

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2434

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2431

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China.

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1662

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum. Lead author: HS Sader presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1817

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents.

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1805

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661

Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections.

Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1671

Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens.

Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1672

Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017).

Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017). Lead author: LR Duncan, presented at the 28th European Congress of Clinical Microbiology and Infections Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1808

Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017).

Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1806

Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016.

Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1140

Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016).

Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016). Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0929

The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016).

The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: AC Gales, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1104

Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13).

Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, Madrid, Spain
# P0606

In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program.

In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0599

Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program.

Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1073

Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016.

Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1043

Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016).

Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101.

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101. Lead author: MD Huband, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
#P0157

Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016.

Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Lead author: MA Pfaller, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0323

Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms.

Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms. Lead author: M Castanheira presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0093

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). by Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M and Sader HS published in Diagn. Microbiol. Infect. Dis. 2018; 91 (1): 77-84

Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa. by Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK and Jones RN published in J. Clin. Microbiol. 2018 in press

Dalbavancin in vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in United States and European hospitals (2011-2016).

Dalbavancin in vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in United States and European hospitals (2011-2016). by Pfaller MA, Flamm RK, Castanheira M, Sader HS and Mendes RE published in Int. J. Antimicrob. Agents. 2018; 51 (4): 608-611

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016. by Pfaller MA, Huband MD, Shortridge D and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (4): e02327

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018 in press

Fungemia surveillance in Denmark demonstrates emergence of Candida non-albicans, higher antifungal usage and resistance rates when compared to other nations.

Fungemia surveillance in Denmark demonstrates emergence of Candida non-albicans, higher antifungal usage and resistance rates when compared to other nations. by Castanheira M published in J. Clin. Microbiol. 2018; 56 (4): e01907

Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015.

Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. by Castanheira M, Duncan LR, Mendes RE, Sader HS and Shortridge D published in Antimicrob. Agents Chemother. 2018; 62 (3): e02125

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). by Pfaller MA, Huband MD, Streit J, Flamm RK and Sader HS Int. J. Antimicrob. Agents 2018; 51 (6): 848-853

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M. Int. J. Antimicrob. Agents. 2018: 52 (2); 144-150

In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016).

In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016). by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS published in Antimicrob. Agents Chemother. 2018 62 (2): e01555

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M publishedin Int. J. Antimicrob. Agents 2018 in press

Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers.

Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. by Sader HS, Mendes RE, Duncan LR, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (3): e02397

The application of in vitro surveillance data for antibacterial dose selection.

The application of in vitro surveillance data for antibacterial dose selection. by Flamm RK, Sader HS, Castanheira M and Jones RN published in Curr Opin Pharmacol 2017; 36:130-138

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates.

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. by Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK and Castanheira M published in Antimicrob. Agents Chemother. 2017; 62 (1): e01856

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility.

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Microb. Drug Resist. 2018; 24 (5): 563-577

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016).

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). by Sader HS, Castanheira M, Shortridge D, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (11): e01045

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015).

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M and Flamm RK published in Braz. J. Infect. Dis. 2017; 21 (6): 627-637